A human immunome-based and parasite genome based bioinformatices approach was used to define candidate HLA-A03 supertype restricted peptides. Immunogenicity of a group of T. gondii HLA-A03 supertype restricted peptides, and therefore the proteins from which they are derived, for immune humans and HLA-A*1101 transgenic mice was demonstrated. These peptides elicit interferon-γ production by human CD8 + T cells. They also elicit interferon γ production by mouse splenocytes when utilized to immunize HLA-A*1101 transgenic mice with a lipopeptide with a universal CD4 + T cell eliciting epitope, PADRE, or in peptide pools with PADRE, Pam 2 Cys and GLA-SE, a novel adjuvant. Immunization studies demonstrate the need for and the efficacy of adjuvants in immunization of these HLA transgenic mice. Immunogenic peptides included KSFKDILPK (SAG1 224-232 ); AML-TAFFLR (GRA6 164-172 ); and RSFKDLLKK (GRA7 134-142 ); STFWBCLLR (SAG2C [13] [14] [15] [16] [17] [18] [19] [20] [21] ; SSAYVFSVK (SPA 250-258 ); and AVVSLLRLLK (SPA 89-98 ). The studies herein provide a foundation for immunosense based vaccines to prevent toxoplasmosis in those with the HLA-A03 supertype and information about how they can be adjuvanted.